|
The Board is tasked with developing a comprehensive strategic plan for Maryland’s life sciences industry, including:
- Promoting life sciences research, development, commercialization and manufacturing in the State
- Promoting collaboration and coordination among life science organizations in Maryland
- Developing a strategy to coordinate state and federal resources to attract private sector investment and job creation in the life sciences
- Developing a strategy to support federal life sciences facilities located in the state, including support for education, transportation, housing and capital investment needs
- Making recommendations to address critical needs in the life sciences, including access to venture capital and capital construction funding.
CHAIR
H. Thomas Watkins, President and Chief Executive Officer of Human Genome Sciences, Inc.
BOARD MEMBERS
Norma M. Allewell, Ph.D., Dean, Chemical and Life Sciences, University of Maryland, College Park
Norka Ruiz Bravo, Ph.D., Deputy Director for Extramural Research, National Institutes of Health (NIH)
Francesca M. Cook, M.P.H., Vice President of Policy and Government Affairs, PharmAthene, Inc.
Stephen Desiderio, M.D., Ph.D., Director, Institute for Basic Biomedical Sciences, The Johns Hopkins University School of Medicine
Lawrence J. Diamond, Mid-Atlantic Senior Vice President, Alexandria Real Estate Equities
David W. Edgerley, Secretary, Maryland Department of Business and Economic Development
David S. Iannucci, Esquire; Director, Baltimore County Department of Economic Development
Philippe Jacon, President, BD Diagnostic Systems
Colonel George W. Korch, Jr., Ph.D., Commander, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
Nina Lamba, Ph.D., Founder and President, CCL Biomedical, Inc.
Hercules Pinkney, Ed.D., Vice President and Provost, Montgomery College-Germantown
David J. Ramsay, D.M., D.Phil., President, University of Maryland, Baltimore
Renée M. Winsky, Executive Director, Maryland Technology Development Corporation
Janet Woodcock, M.D., Deputy Commissioner and Chief Medical Officer, Food and Drug Administration
Maryland’s Biotechnology Industry
Maryland is home to more than 370 bioscience companies, one of the fastest growing clusters in the United States. Maryland’s private-sector bioscience companies employ approximately 30,000; an additional 30,000 workers are employed at federal and academic institutions. Maryland ranks second worldwide for initiatives aimed at drawing and retaining biotechnology companies including building research parks, investing public funds, and providing tax incentives. Much of Maryland’s success and competitiveness can be attributed to the State’s significant commitment and long-term investment in bioscience infrastructure – totaling more than $450 million. The recipient of $7.2 billion in federal research and development obligations annually, Maryland continues to be a leader in per capita spending in the nation.
Maryland was recently ranked second in the nation by the Milken Institute for biopharmaceutical innovation. Maryland has been also recognized by Ernst & Young as one of the top three centers for biodefense in the United States. Maryland is home to U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, a leading facility for biodefense vaccine research; University of Maryland at Baltimore (UMB) Center for Vaccine Development, the only university vaccine center in the world engaged in the full range of vaccinology; National Institutes of Health Vaccine Research Center; University of Maryland Biotechnology Institute; and Institute for Vaccine Safety at the Johns Hopkins Bloomberg School of Public Health.
|
|
